Works matching AU Abeykoon, Jithma
Results: 56
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Clinical features and outcomes in primary nervous system histiocytic neoplasms.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00693-7
- By:
- Publication type:
- Article
Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00685-7
- By:
- Publication type:
- Article
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00452-0
- By:
- Publication type:
- Article
IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S401, doi. 10.1016/S2152-2650(21)01906-6
- By:
- Publication type:
- Article
Poster: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01536-6
- By:
- Publication type:
- Article
Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01277-5
- By:
- Publication type:
- Article
Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e38, doi. 10.1016/j.clml.2019.09.058
- By:
- Publication type:
- Article
Outcome of Very Young (≤ 40 Years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e89, doi. 10.1016/j.clml.2017.03.159
- By:
- Publication type:
- Article
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221093962
- By:
- Publication type:
- Article
New developments in the management of Waldenström macroglobulinemia.
- Published in:
- Cancer Management & Research, 2017, v. 9, p. 73, doi. 10.2147/CMAR.S94059
- By:
- Publication type:
- Article
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 98, doi. 10.1111/bjh.14826
- By:
- Publication type:
- Article
Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Classical and non‐classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findings.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 3, p. 454, doi. 10.1111/bjh.18422
- By:
- Publication type:
- Article
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 1, p. 95, doi. 10.1111/bjh.18298
- By:
- Publication type:
- Article
Mimics of Erdheim–Chester disease.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. 984, doi. 10.1111/bjh.17949
- By:
- Publication type:
- Article
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 210, doi. 10.1111/bjh.17691
- By:
- Publication type:
- Article
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 2, p. 380, doi. 10.1111/bjh.17195
- By:
- Publication type:
- Article
Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 542, doi. 10.1111/bjh.17225
- By:
- Publication type:
- Article
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 3, p. 394, doi. 10.1111/bjh.16168
- By:
- Publication type:
- Article
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 3, p. 274, doi. 10.1002/ajh.25697
- By:
- Publication type:
- Article
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1384, doi. 10.1002/ajh.25254
- By:
- Publication type:
- Article
Reply to Castillo et al.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 3, p. E71, doi. 10.1002/ajh.25029
- By:
- Publication type:
- Article
<italic>MYD88</italic> mutation status does not impact overall survival in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. 187, doi. 10.1002/ajh.24955
- By:
- Publication type:
- Article
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1146, doi. 10.1002/ajh.24883
- By:
- Publication type:
- Article
POEMS syndrome: An elusive diagnosis.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1269, doi. 10.1002/ajh.24845
- By:
- Publication type:
- Article
C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 1, p. 132, doi. 10.1111/ejh.14212
- By:
- Publication type:
- Article
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 458, doi. 10.1111/ejh.13682
- By:
- Publication type:
- Article
Neurological Manifestations of Histiocytic Disorders.
- Published in:
- Current Neurology & Neuroscience Reports, 2023, v. 23, n. 6, p. 277, doi. 10.1007/s11910-023-01272-4
- By:
- Publication type:
- Article
Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide.
- Published in:
- Case Reports in Hematology, 2018, p. 1, doi. 10.1155/2018/9615834
- By:
- Publication type:
- Article
Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia.
- Published in:
- Leukemia & Lymphoma, 2023, v. 64, n. 8, p. 1490, doi. 10.1080/10428194.2023.2214026
- By:
- Publication type:
- Article
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States.
- Published in:
- Leukemia & Lymphoma, 2022, v. 63, n. 12, p. 2879, doi. 10.1080/10428194.2022.2102623
- By:
- Publication type:
- Article
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
- Published in:
- Leukemia & Lymphoma, 2021, v. 62, n. 2, p. 308, doi. 10.1080/10428194.2020.1832669
- By:
- Publication type:
- Article
Predictors of short-term survival in Waldenström Macroglobulinemia.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Low-dose vemurafenib monotherapy in BRAF<sup>V600E</sup>-mutated Erdheim-Chester disease.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Non-tender recurrent scrotal cellulitis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
BRAF testing modalities in histiocytic disorders: Comparative analysis and proposed testing algorithm.
- Published in:
- American Journal of Clinical Pathology, 2023, v. 160, n. 5, p. 483, doi. 10.1093/ajcp/aqad076
- By:
- Publication type:
- Article
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma.
- Published in:
- Oncologist, 2024, v. 29, n. 12, p. e1779, doi. 10.1093/oncolo/oyae255
- By:
- Publication type:
- Article
Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 144, doi. 10.1093/oncolo/oyab031
- By:
- Publication type:
- Article
Efficacy of BRAF‐Inhibitor Therapy in BRAF<sup>V600E</sup>‐Mutated Adult Langerhans Cell Histiocytosis.
- Published in:
- Oncologist, 2020, v. 25, n. 12, p. 1001, doi. 10.1002/onco.13541
- By:
- Publication type:
- Article
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis.
- Published in:
- Amyloid, 2017, v. 24, p. 50, doi. 10.1080/13506129.2017.1286584
- By:
- Publication type:
- Article
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 5, p. 871, doi. 10.1002/ajh.27263
- By:
- Publication type:
- Article
Bortezomib and daratumumab in refractory autoimmune hemolytic anemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E263, doi. 10.1002/ajh.27025
- By:
- Publication type:
- Article
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 293, doi. 10.1002/ajh.26441
- By:
- Publication type:
- Article
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 12, p. 1604, doi. 10.1002/ajh.26355
- By:
- Publication type:
- Article
Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 945, doi. 10.1002/ajh.26210
- By:
- Publication type:
- Article